These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 30052654)

  • 1. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
    Yuille S; Reichardt N; Panda S; Dunbar H; Mulder IE
    PLoS One; 2018; 13(7):e0201073. PubMed ID: 30052654
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ahmed S; Busetti A; Fotiadou P; Vincy Jose N; Reid S; Georgieva M; Brown S; Dunbar H; Beurket-Ascencio G; Delday MI; Ettorre A; Mulder IE
    Front Cell Neurosci; 2019; 13():402. PubMed ID: 31619962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic modulation of gut microbiota improves post-myocardial infarct tissue repair in rats via butyric acid-mediated histone deacetylase inhibition.
    Song T; Guan X; Wang X; Qu S; Zhang S; Hui W; Men L; Chen X
    FASEB J; 2021 Mar; 35(3):e21385. PubMed ID: 33565193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon.
    Waldecker M; Kautenburger T; Daumann H; Busch C; Schrenk D
    J Nutr Biochem; 2008 Sep; 19(9):587-93. PubMed ID: 18061431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone Deacetylase Inhibition by Gut Microbe-Generated Short-Chain Fatty Acids Entrains Intestinal Epithelial Circadian Rhythms.
    Fawad JA; Luzader DH; Hanson GF; Moutinho TJ; McKinney CA; Mitchell PG; Brown-Steinke K; Kumar A; Park M; Lee S; Bolick DT; Medlock GL; Zhao JY; Rosselot AE; Chou CJ; Eshleman EM; Alenghat T; Hong CI; Papin JA; Moore SR
    Gastroenterology; 2022 Nov; 163(5):1377-1390.e11. PubMed ID: 35934064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
    Felice C; Lewis A; Armuzzi A; Lindsay JO; Silver A
    Aliment Pharmacol Ther; 2015 Jan; 41(1):26-38. PubMed ID: 25367825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer?
    Chattopadhyay I; Gundamaraju R; Jha NK; Gupta PK; Dey A; Mandal CC; Ford BM
    Dis Markers; 2022; 2022():2941248. PubMed ID: 35178126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFFECT OF CARBOXYLIC ACIDS OF GUT MICROBIAL ORIGIN ON HOST CELL PROLIFERATION IN ORGANOTYPIC TISSUE CULTURES.
    Vakhitov TY; Chalisova N; Sitkin SI
    Eksp Klin Gastroenterol; 2016 Jul; 12(12):73-82. PubMed ID: 29889427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butyrate Produced by Commensal Bacteria Down-Regulates
    Martin-Gallausiaux C; Larraufie P; Jarry A; Béguet-Crespel F; Marinelli L; Ledue F; Reimann F; Blottière HM; Lapaque N
    Front Immunol; 2018; 9():2838. PubMed ID: 30619249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a butyrate-producing bacterium.
    Zhang Q; Wu Y; Wang J; Wu G; Long W; Xue Z; Wang L; Zhang X; Pang X; Zhao Y; Zhao L; Zhang C
    Sci Rep; 2016 Jun; 6():27572. PubMed ID: 27264309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiotic reduction of brain histone deacetylase (HDAC) activity and olanzapine-mediated weight gain in rats, are acetate independent.
    Kao AC; Chan KW; Anthony DC; Lennox BR; Burnet PW
    Neuropharmacology; 2019 May; 150():184-191. PubMed ID: 30763656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone-deacetylase inhibition and butyrate formation: Fecal slurry incubations with apple pectin and apple juice extracts.
    Waldecker M; Kautenburger T; Daumann H; Veeriah S; Will F; Dietrich H; Pool-Zobel BL; Schrenk D
    Nutrition; 2008 Apr; 24(4):366-74. PubMed ID: 18262392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation.
    He Q; Han C; Huang L; Yang H; Hu J; Chen H; Dou R; Ren D; Lin H
    J Cell Mol Med; 2020 Aug; 24(16):9349-9361. PubMed ID: 32628809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
    Li Q; Ding C; Meng T; Lu W; Liu W; Hao H; Cao L
    J Pharmacol Sci; 2017 Dec; 135(4):148-155. PubMed ID: 29233468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation.
    Hinnebusch BF; Meng S; Wu JT; Archer SY; Hodin RA
    J Nutr; 2002 May; 132(5):1012-7. PubMed ID: 11983830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein-Taybi Syndrome.
    Di Fede E; Ottaviano E; Grazioli P; Ceccarani C; Galeone A; Parodi C; Colombo EA; Bassanini G; Fazio G; Severgnini M; Milani D; Verduci E; Vaccari T; Massa V; Borghi E; Gervasini C
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.